Publications by authors named "S Meeks"
Introduction: Eptacog beta is a novel human recombinant FVIIa approved for use in the United States, European Union, United Kingdom and Mexico for the treatment and control of bleeding in patients with haemophilia A or B with inhibitors (≥12 years). It is also indicated for perioperative care in the same patient population in Europe and the United Kingdom.
Aim: To assess the incidence of rebleeding and review treatment outcomes in subjects with haemophilia with inhibitors enrolled in the phase 3 PERSEPT 1 clinical trial.
Background: Immune tolerance induction (ITI) is the gold standard for inhibitor eradication to restore the clinical efficacy of factor replacement therapy in haemophilia. However, as ITI often requires frequent administration over extended periods, it can be considered burdensome for patients and healthcare resources. Therefore, there is a need to optimise ITI treatment, particularly in patients who failed previous ITI attempts.
View Article and Find Full Text PDFArticle Synopsis
- The study analyzes the formation of contrails from ammonia-powered engines compared to traditional jet fuel engines, focusing on thermodynamic processes like supersaturation and ice nucleation.
- It calculates how moisture from exhaust affects atmospheric conditions, determining the potential for contrail visibility based on temperature and humidity changes.
- Findings suggest that ammonia contrails are less dense but can form at lower altitudes and last longer due to higher moisture content, despite not producing soot which typically aids contrail formation.
Article Synopsis
- The study focuses on how IgM antibodies, which are produced in patients with hemophilia A, interact with factor VIII (FVIII) and potentially influence the development of harmful IgG inhibitors.
- Researchers identified specific FVIII-targeting IgM antibodies from mice and analyzed their binding capabilities using advanced lab techniques.
- Results indicated that while the IgM antibodies can bind to FVIII, they do not significantly influence the production of IgG inhibitors, suggesting that IgM's role may be limited in this context.